Download Files:
Products Details
Product Description
– SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway[1].
Web ID
– HY-107595
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C18H19NO5
References
– [1]Duan Z, et al. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol. 2007;72(5):1137-1145.
CAS Number
– 960201-81-4
Molecular Weight
– 329.35
SMILES
– O=C([C@H]1[C@H](C2=O)N([C@H](C=C2)[C@H]1C(OC)=O)CC3=CC=CC=C3)OC
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;JAK;STAT
Isoform
– JAK2;STAT3
Pathway
– Apoptosis;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
